ArticleJournal of virology2007
Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.
Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 67 citations in OpenAlex.
- Review
- Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.Antimicrobial agents and chemotherapy · 2014Article
- Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Antimicrobial agents and chemotherapy · 2014Article
- In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.Antimicrobial agents and chemotherapy · 2013Article
- Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.Journal of virology · 2013Article
- Inhibition of hepatitis C virus replication by Monascus pigment derivatives that interfere with viral RNA polymerase activity and the mevalonate biosynthesis pathway.The Journal of antimicrobial chemotherapy · 2012Article
- Discovery of naturally occurring aurones that are potent allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase.Journal of medicinal chemistry · 2011Article
- Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Antimicrobial agents and chemotherapy · 2011Article
- De novo polymerase activity and oligomerization of hepatitis C virus RNA-dependent RNA-polymerases from genotypes 1 to 5.PloS one · 2011Article
- Chiral gold(I) vs chiral silver complexes as catalysts for the enantioselective synthesis of the second generation GSK-hepatitis C virus inhibitor.Beilstein journal of organic chemistry · 2011Article
- Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Viruses · 2010Article
- Inhibition of dengue virus polymerase by blocking of the RNA tunnel.Journal of virology · 2010Article
- Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor.Biochemistry · 2010Article
- 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.Journal of virology · 2010Article
- Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.The Journal of biological chemistry · 2009Article
- 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.Antimicrobial agents and chemotherapy · 2008Article
- Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.Antimicrobial agents and chemotherapy · 2008Article
- Functional characterization of fingers subdomain-specific monoclonal antibodies inhibiting the hepatitis C virus RNA-dependent RNA polymerase.The Journal of biological chemistry · 2008Article
- Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes.Antimicrobial agents and chemotherapy · 2008Article
- Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.Topics in antiviral medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for hepatitis C virus polymerase inhibitors has resulted in the identification of several nonnucleoside binding pockets. The shape and nature of these binding sites differ across and even within diverse hepatitis C virus genotypes. These differences confront antiviral drug discovery with the challenge of finding compounds that are capable of inhibition in variable binding pockets. To address this, we have established a hepatitis C virus mutant and genotypic recombinant polymerase panel as a means of guiding medicinal chemistry through the elucidation of the site of action of novel inhibitors and profiling against genotypes. Using a genotype 1b backbone, we demonstrate that the recombinant P495L, M423T, M414T, and S282T mutant enzymes can be used to identify the binding site of an acyl pyrrolidine analog. We assess the inhibitory activity of this analog and other nonnucleoside inhibitors with our panel of enzyme isolates generated from clinical sera representing genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.